Guobang Pharma Statistics

Total Valuation

Guobang Pharma has a market cap or net worth of CNY 11.39 billion. The enterprise value is 10.11 billion.

Market Cap	11.39B
Enterprise Value	10.11B

Important Dates

The next estimated earnings date is Friday, August 15, 2025.

Earnings Date	Aug 15, 2025
Ex-Dividend Date	Jun 14, 2024

Share Statistics

Guobang Pharma has 558.37 million shares outstanding. The number of shares has increased by 1.07% in one year.

Current Share Class	558.37M
Shares Outstanding	558.37M
Shares Change (YoY)	+1.07%
Shares Change (QoQ)	+0.44%
Owned by Insiders (%)	12.67%
Owned by Institutions (%)	5.32%
Float	192.83M

Valuation Ratios

The trailing PE ratio is 14.36 and the forward PE ratio is 12.17.

PE Ratio	14.36
Forward PE	12.17
PS Ratio	1.90
PB Ratio	1.38
P/TBV Ratio	1.44
P/FCF Ratio	113.21
P/OCF Ratio	26.24
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.77, with an EV/FCF ratio of 100.53.

EV / Earnings	12.67
EV / Sales	1.69
EV / EBITDA	7.77
EV / EBIT	12.03
EV / FCF	100.53

Financial Position

The company has a current ratio of 2.51, with a Debt / Equity ratio of 0.13.

Current Ratio	2.51
Quick Ratio	1.57
Debt / Equity	0.13
Debt / EBITDA	0.81
Debt / FCF	10.47
Interest Coverage	32.98

Financial Efficiency

Return on equity (ROE) is 10.04% and return on invested capital (ROIC) is 5.84%.

Return on Equity (ROE)	10.04%
Return on Assets (ROA)	4.88%
Return on Invested Capital (ROIC)	5.84%
Return on Capital Employed (ROCE)	9.74%
Revenue Per Employee	1.50M
Profits Per Employee	199,311
Employee Count	4,003
Asset Turnover	0.56
Inventory Turnover	3.13

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +15.47% in the last 52 weeks. The beta is 0.38, so Guobang Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.38
52-Week Price Change	+15.47%
50-Day Moving Average	19.73
200-Day Moving Average	19.72
Relative Strength Index (RSI)	61.28
Average Volume (20 Days)	3,428,869

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Guobang Pharma had revenue of CNY 5.99 billion and earned 797.84 million in profits. Earnings per share was 1.42.

Revenue	5.99B
Gross Profit	1.45B
Operating Income	840.13M
Pretax Income	902.77M
Net Income	797.84M
EBITDA	1.30B
EBIT	840.13M
Earnings Per Share (EPS)	1.42

Full Income Statement

Balance Sheet

The company has 2.33 billion in cash and 1.05 billion in debt, giving a net cash position of 1.28 billion or 2.29 per share.

Cash & Cash Equivalents	2.33B
Total Debt	1.05B
Net Cash	1.28B
Net Cash Per Share	2.29
Equity (Book Value)	8.26B
Book Value Per Share	14.59
Working Capital	3.77B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 433.85 million and capital expenditures -333.29 million, giving a free cash flow of 100.57 million.

Operating Cash Flow	433.85M
Capital Expenditures	-333.29M
Free Cash Flow	100.57M
FCF Per Share	0.18

Full Cash Flow Statement

Margins

Gross margin is 24.18%, with operating and profit margins of 14.02% and 13.31%.

Gross Margin	24.18%
Operating Margin	14.02%
Pretax Margin	15.07%
Profit Margin	13.31%
EBITDA Margin	21.71%
EBIT Margin	14.02%
FCF Margin	1.68%

Dividends & Yields

This stock pays an annual dividend of 0.60, which amounts to a dividend yield of 2.94%.

Dividend Per Share	0.60
Dividend Yield	2.94%
Dividend Growth (YoY)	-49.75%
Years of Dividend Growth	n/a
Payout Ratio	24.09%
Buyback Yield	-1.07%
Shareholder Yield	1.89%
Earnings Yield	7.01%
FCF Yield	0.88%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Guobang Pharma has an Altman Z-Score of 3.89.

Altman Z-Score	3.89
Piotroski F-Score	n/a